Compare Crispr Therapeutics AG (CRSP) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs McDonald's Corp — how do they compare? Crispr Therapeutics AG trades at $50.63 (market cap $4.97B), while McDonald's Corp trades at $269.25 (market cap $191.08B). The key difference: McDonald's Corp is far larger — about 38.4× Crispr Therapeutics AG's market cap, and McDonald's Corp pays a 2.77% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MCD | |
|---|---|---|
Market Cap | $4.97B | $191.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $341.06 |
52-Week Low | $44.34 | $264.54 |
Enterprise Value | $3.32B | $244.79B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
McDonald's (MCD) trades at $268.94, down 2.06% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly EPS results, with a miss in Q3 2025 but beats in Q4 2025 and Q1 2026. Revenue grew to $26.89 billion in 2025, with a net income margin of 31.62%. Recent news highlights the launch of the McDonald's NEXT strategy focusing on automation and better food to win back customers.
The outlook remains supported by strong analyst consensus with a $325.50 price target and 59.68% buy ratings, but risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock offers a dividend yield with a recent $1.86 payout, appealing for income-focused investors amid current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
